NTD Progress Is Outrunning the Budget

WHO’s new global assessment shows that 63 countries have eliminated at least one neglected tropical disease, compared with 42 at the end of 2020. Yet available resources remain 30% below pre-pandemic levels, financing is dangerously concentrated among a handful of donors, and most disease-specific targets remain off track. Global health is making measurable progress while…

November 20, 2026
Editorial
Progress against neglected tropical diseases depends on sustained community treatment, diagnostic access, surveillance and the long-term financing of programmes serving vulnerable populations.Halfpoint / Shutterstock.com

IPM Take

Global health is approaching a dangerous contradiction: it has increasingly effective tools for eliminating neglected tropical diseases while allowing the financing that delivers those tools to deteriorate.

The latest WHO assessment offers substantial evidence that elimination programmes work. More countries have reached elimination milestones, and fewer people require interventions. But those gains are becoming vulnerable to funding instability, shrinking international support and persistent weaknesses in primary-care integration.

Executive Summary

WHO released its 2026 global report on neglected tropical diseases on 4 November, presenting a midterm assessment of the 2021–2030 road map.

By June 2026, 63 countries had eliminated at least one NTD, up from 42 at the end of 2020. The number of people requiring interventions fell to 1.41 billion in 2024, a reduction of 36% since 2010.

However, only three disease-specific indicators had reached their 2025 milestones. Neither Guinea worm disease nor yaws eradication is currently on track. Available resources remain approximately 30% below pre-COVID-19 levels, while a small group of donors accounted for nearly 80% of international development assistance for NTDs between 2018 and 2024.

Why it matters

  • Governments and donors: Financing interruptions can reverse elimination gains and disrupt treatment, surveillance and vector-control programmes.
  • Patients and communities: Service interruptions are particularly damaging where disease burden is concentrated among populations with limited access to routine healthcare.
  • Researchers and industry: New diagnostics and medicines will have limited population impact without procurement, delivery infrastructure and sustained implementation financing.

Neglected tropical diseases have produced some of global health’s clearest evidence that sustained public-health investment works. Diseases once associated with large-scale disability, disfigurement and poverty have been pushed towards elimination through treatment campaigns, improved surveillance, vector control and community-based programmes.

The latest WHO report shows that this progress is substantial rather than merely aspirational. Sixty-three countries have now eliminated at least one neglected tropical disease, while the number of people requiring interventions has continued to decline.

That success should be celebrated. It should also make current financing decisions considerably harder to defend.

WHO reports that the resources available for neglected tropical diseases remain approximately 30% below pre-pandemic levels. International assistance is heavily concentrated among a relatively small number of donors, creating vulnerability when political priorities or development budgets change. Interruptions have already affected mass treatment, case management, surveillance and vector control, while donated medicines can be left unused when programmes lack the operational capacity to distribute them.

This is a particularly damaging moment for funding instability because elimination programmes become more demanding as disease prevalence falls. When infections are widespread, identifying high-burden populations and demonstrating progress can be comparatively straightforward. Near elimination, the remaining cases are often concentrated in remote, marginalised or conflict-affected communities where surveillance, referral and treatment are more expensive to maintain.

The need for precision therefore increases as the overall disease burden decreases.

There are also reasons to be optimistic about medical innovation. WHO highlights progress in child-friendly treatments for schistosomiasis, medicines for leishmaniasis, new tools for human African trypanosomiasis and vaccines against several vector-borne infections. Yet scientific progress cannot automatically compensate for financial and institutional weakness. A medicine that has reached regulatory approval but cannot be procured or delivered consistently remains an incomplete public-health intervention.

The report also exposes uneven implementation across diseases. Only three disease-specific indicators reached their 2025 milestones, while neither of the two eradication programmes is on schedule. Progress against sleeping sickness and Guinea worm disease contrasts with the expanding burden of dengue and other challenges linked to climate, population movement and weakening health systems.

The political response should not be another collection of isolated disease campaigns. WHO is increasingly advocating the integration of NTD services into primary healthcare, national health strategies and universal health coverage packages. That approach can make delivery more sustainable while reducing dependence on externally financed vertical programmes.

But integration cannot become a justification for removing dedicated resources before national systems have the capacity to absorb them. Transferring responsibility without transferring money, workforce and expertise is not sustainability. It is administrative abandonment.

The global community is approaching the midpoint between demonstrated success and unfinished ambition. Governments already possess evidence that elimination is possible.

The question is whether they are willing to finance the final, most difficult stages of the work.

Source & Evidence